These receptors, together with enhanced expression of other signaling molecules, particularly Gγ9 (El-Haibi et al., 2013) and ARF1 (Davis et al., 2016), may partially contribute to hyper-activation of oncogenic MAPK pathway in prostate cancer patients. Here, ARF1 is linked to prostate carcinoma.